| 27.44 -0.02 (-0.07%) | 06-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34 | 1-year : | 39.71 |
| Resists | First : | 29.11 | Second : | 34 |
| Pivot price | 26.58  |
|||
| Supports | First : | 22.96 | Second : | 19.15 |
| MAs | MA(5) : | 27.42 |
MA(20) : | 25.05 |
| MA(100) : | 13.84 |
MA(250) : | 7.87 |
|
| MACD | MACD : | 2.2 |
Signal : | 2.4 |
| %K %D | K(14,3) : | 80.4 |
D(3) : | 81.3 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 29.11 | Low : | 1.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ WGS ] has closed below upper band by 38.4%. Bollinger Bands are 15.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.63 - 28.79 | 28.79 - 28.92 |
| Low: | 26.58 - 26.8 | 26.8 - 26.98 |
| Close: | 27.12 - 27.44 | 27.44 - 27.71 |
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Mon, 24 Jun 2024
GeneDx Holdings Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements ... - Quantisnow
Wed, 19 Jun 2024
GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 2646 Shares - Defense World
Wed, 19 Jun 2024
GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 7683 Shares - Defense World
Tue, 18 Jun 2024
Kevin Feeley Sells 2,646 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock - MarketBeat
Wed, 12 Jun 2024
GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors - Simply Wall St
Tue, 11 Jun 2024
Kevin Feeley Sells 895 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 26 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 31.3 (%) |
| Held by Institutions | 55.9 (%) |
| Shares Short | 1,170 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -4.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.92 |
| Profit Margin | -60.9 % |
| Operating Margin | -21.9 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -50.5 % |
| Qtrly Rev. Growth | 44.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.48 |
| EBITDA (p.s.) | -3.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -141 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -5.53 |
| PEG Ratio | 0 |
| Price to Book value | 3.46 |
| Price to Sales | 3.23 |
| Price to Cash Flow | -5.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|